KPV Legal Status: an FDA meeting is not approval

What Is True Now: KPV Isn’t Approved

KPV is sold for lab research. It isn’t an FDA-approved medicine. Some pharmacies may make a drug for one named person, but federal rules limit the raw ingredients.

KPV’s nomination has been withdrawn, but FDA still records safety concerns ^[18]. The FDA’s July 2026 advisory meeting has already taken place ^[19]. An advisory meeting grants no FDA drug approval.

A withdrawn nomination does not settle whether an ingredient meets compounding rules. We won’t guess what the FDA may decide. This page tells you where the matter stands now.

What Pharmacies May Do With KPV Today

KPV is a three-part piece of a natural hormone. It is sold for research, and the FDA hasn’t approved it to treat illness. Approval for a finished drug differs from permission to mix one in a pharmacy. Withdrawing its nomination did not give KPV FDA drug approval or establish permission to compound it ^[18].

A pharmacy can use a raw ingredient only if federal law allows it. The ingredient may have an official drug-book entry, be part of an approved drug, or sit on an FDA list. That list names raw ingredients pharmacies may use. KPV isn’t on it.

A maker may ask the FDA to review an ingredient for that list. The FDA’s pharmacy advisers give their view. KPV came up for that review in July 2026, but that isn’t approval.

What the Two Pharmacy-Mixing Rules Cover

Federal law gives pharmacies two main ways to mix drugs. One covers a medicine made for one named person with a valid prescription. State-licensed pharmacies and doctors use that rule. The other covers registered sites that make larger batches under FDA checks.

The FDA once put proposed raw ingredients into Category 1 or Category 2 ^[18]. The first group could sometimes be used while review continued, if other rules were met. The second group held ingredients with major safety concerns. On January 7, 2025, the FDA stopped sorting newly proposed ingredients this way ^[17].

FDA lists KPV among withdrawn nominations and retains the safety concerns beside its entry ^[18]. FDA also put KPV on the list for its July 2026 advisory meeting. KPV is not on the FDA list of raw ingredients a pharmacy may use. An ad may blur those facts, but the law does not.

What the July 2026 FDA Meeting Could Decide

The FDA named KPV for a public meeting on July 23-24, 2026. Two chemical forms of KPV were on the agenda for its pharmacy advisers. The question put to them was whether KPV belongs on the list of raw ingredients pharmacies may use. The same agenda named BPC-157, TB-500, and MOTs-C.

The advisers do not make the final rule. A place on their meeting list doesn’t change KPV’s standing. FDA staff had proposed against adding KPV. The FDA may act later, but no result is set.

A seller may have treated the 2026 date as a coming approval. The FDA’s 2026 notice made no such promise. We won’t put an answer in the agency’s mouth. For you, the useful fact is that the FDA hasn’t announced an outcome for KPV.

Holding the meeting proves only that KPV was on the agenda. No tally of the advisers’ votes had appeared by September 2026. Nor has the FDA said what it means to do next.

How a Doctor and Pharmacy Handle a Mixed Medicine

Speaking generally — not about KPV specifically, and not as medical or legal advice — a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office or batch use, sourced from an FDA-registered 503B outsourcing facility.

Telehealth can serve as the front-end channel for that prescriber evaluation, but it is a route to a consultation and prescription — not a separate legal status. Telehealth does not expand which substances may be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription. And the framework's gate always applies: a compounder may use a requested ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient FDA lists in Category 2 over significant safety risks gets no interim pass from the agency for routine 503A compounding. This site endorses no pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain any substance outside the lawful framework.

For KPV, prescription consultations at mypromise.com are provided by Promise Peptides, which is now prescribing it. Each person’s health is assessed by a U.S.-licensed clinician, who may issue a prescription or turn the request down. The service accepts U.S. patients only; both the patient’s state and the treatment under consideration limit the options. A compounded medicine has not received FDA approval. FDA’s withdrawn KPV nomination still carries the agency’s safety concerns ^[18].

What the FDA Papers Don’t Back Up

Leaving Category 2 through a withdrawn nomination is not placement in Category 1 ^[18]. FDA’s withdrawn-nomination table includes KPV, BPC-157, and TB-500. The safety concerns remain beside those entries, so withdrawal cannot be read as permission to compound them ^[18].

The July 2026 agenda included KPV, BPC-157, and TB-500 ^[19]. That meeting has passed, and FDA has posted no record of the advisers’ votes. A later ruling could change the facts, but none has been made.

This page gives general facts, not medical or legal advice. Nothing here is offered for sale. You can also read the KPV studies or the common questions.

If a legal claim affects your choice, check the dated FDA page. Website claims can grow stale. The agency’s own page shows what has changed.